Advertisement
Screener

Arcus Biosciences, Inc. (RCUS) Graph

RCUS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $113.00M; Operating expenses $137.00M; Income tax $0.00.
  • 2026-03-31: Revenue (m); Research and development $122.00M; Operating expenses $151.00M; Income tax $0.00.
  • 2025-12-31: Revenue (m); Research and development $121.00M*; Operating expenses $147.00M*; Income tax $0.00*.
  • 2025-09-30: Revenue (m); Research and development $141.00M; Operating expenses $168.00M; Income tax $0.00.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$113.00M$137.00M$0.00-$91.00M
2026-03-31(m)$122.00M$151.00M$0.00-$128.00M
2025-12-31(m)$121.00M*$147.00M*$0.00*-$106.00M*
2025-09-30(m)$141.00M$168.00M$0.00-$135.00M
2025-06-30(m)$139.00M$168.00M$0.00$0.00
2025-03-31(m)$122.00M$150.00M$0.00-$112.00M
2024-09-30(m)$123.00M$153.00M$0.00-$92.00M
2024-06-30(m)$115.00M$145.00M$0.00-$93.00M
2024-03-31(m)$109.00M$161.00M$0.00-$4.00M
2023-09-30$32.00M$82.00M$112.00M$2.00M-$71.00M
2023-06-30$29.00M$84.00M$112.00M$1.00M-$75.00M
2023-03-31$25.00M$81.00M$111.00M$2.00M-$80.00M
2022-09-30$33.00M$77.00M$103.00M$0.00-$65.00M
2022-06-30$27.00M$70.00M$96.00M$0.00-$67.00M
2022-03-31$18.00M$61.00M$85.00M$1.00M-$68.00M
2021-09-30$9.46M$71.25M$87.60M$0.00-$77.97M
2021-06-30$9.46M$68.77M$85.60M$0.00-$75.97M
2021-03-31$9.46M$66.39M$82.21M$0.00-$72.59M
2020-12-31$9.49M(m)$61.50M(m)-$51.85M
2020-09-30$64.53M$51.80M$62.98M(m)$1.82M
2020-06-30$1.75M$35.69M$47.13M(m)-$45.07M
2020-03-31$1.75M$23.14M$30.15M(m)-$27.75M
2019-12-31$9.75M(m)$27.28M(m)-$16.60M
2019-09-30$1.75M$17.24M$25.00M(m)-$22.35M
2019-06-30$1.75M$25.00M$30.91M(m)-$28.09M
2019-03-31$1.75M$15.55M$20.52M(m)-$17.67M
2018-12-31$1.56M(m)$15.05M(m)-$12.29M
2018-09-30$4.29M$12.86M$16.44M(m)-$10.81M
2018-06-30$1.25M$13.70M$17.15M(m)-$13.53M
2018-03-31$1.25M$11.65M$14.58M(m)-$12.95M
2017-12-31$1.25M(m)$14.59M(m)-$13.21M
2017-09-30$163.00K$21.43M$23.30M(m)-$23.12M
2017-06-30(m)$7.83M$9.66M(m)-$9.55M
2017-03-31(m)$5.80M$7.30M(m)-$7.20M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$235.00M$288.00M$0.00-$219.00M
2025-06-30(m)$261.00M$318.00M$0.00-$112.00M
2024-06-30(m)$224.00M$306.00M$0.00-$97.00M
2023-06-30$54.00M$165.00M$223.00M$3.00M-$155.00M
2022-06-30$45.00M$131.00M$181.00M$1.00M-$135.00M
2021-06-30$18.92M$135.16M$167.81M$0.00-$148.56M
2020-06-30$3.50M$58.84M$77.28M(m)-$72.83M
2019-06-30$3.50M$40.55M$51.43M(m)-$45.76M
2018-06-30$2.50M$25.35M$31.73M(m)-$26.49M
2017-06-30(m)$13.64M$16.96M(m)-$16.75M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$402.00M$486.00M$0.00-$247.00M
2024-09-30(m)$347.00M$459.00M$0.00-$189.00M
2023-09-30$86.00M$247.00M$335.00M$5.00M-$226.00M
2022-09-30$78.00M$208.00M$284.00M$1.00M-$200.00M
2021-09-30$28.38M$206.41M$255.40M$0.00-$226.54M
2020-09-30$68.03M$110.64M$140.25M(m)-$71.00M
2019-09-30$5.25M$57.80M$76.43M(m)-$68.11M
2018-09-30$6.79M$38.21M$48.17M(m)-$37.30M
2017-09-30$163.00K$35.07M$40.26M(m)-$39.87M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$523.00M$633.00M$0.00-$353.00M
2024-12-31(m)$448.00M$588.00M$1.00M-$283.00M
2023-12-31(m)$340.00M$457.00M$6.00M-$307.00M
2022-12-31(m)$288.00M$392.00M$1.00M-$267.00M
2021-12-31$383.00M$257.00M$329.00M$2.00M$53.00M
2020-12-31$78.00M$159.00M$202.00M(m)-$123.00M
2019-12-31$15.00M$78.48M$103.71M(m)-$84.71M
2018-12-31$8.35M$49.65M$63.21M(m)-$49.59M
2017-12-31$1.41M$47.22M$54.85M(m)-$53.08M
2016-12-31(m)$14.25M$18.18M(m)-$17.97M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36